



VentriPoint Diagnostics Ltd.

November 05 2018

VentriPoint Diagnostics reveals that University of Chicago will assess its heart analysis system

VentriPoint Diagnostics Ltd (CVE:VPT) told investors that the University of Chicago's medical centre is to assess the its innovative VMS plus heart analysis system.

With the recent market clearance from the key FDA, Chicago will be one of the first sites to evaluate and publish on the performance of the VMS+ system compared to MRI for all four cardiac chambers, spearheaded by Dr Roberto Lang, said the company.

"We are very pleased to have the VMS+ system installed in a very busy clinical environment such as the Department of Medicine at the University of Chicago," said Desmond Hirson, president of Ventripoint.

"We believe that our product in the hands of the non-invasive cardiac imaging laboratory under the direction of Dr. Lang , will make a valuable difference to patient outcomes."

The VMS+ system uses standard 2D echocardiogram images and Artificial Intelligence (AI) to render 3D volumes for all four chambers of the heart providing clinicians with a more efficient and cost-effective method for evaluating cardiac volumes and ejection fractions.

Dr Lang is an internationally renowned cardiologist and specialist in echocardiography, the study of heart function using sound waves.

He uses vast knowledge of cardiac imaging techniques to evaluate patients with a wide variety of heart conditions, including heart failure and valve disease, noted Ventripoint.

Dr George Adams, chief executive of Ventripoint, noted that Dr Lang had been "one of the leading doctors" who encouraged the firm to expand the VMS to include all four chambers of the heart and not just the RV to address the unmet need in many heart conditions.

"We have proven to the FDA that the VMS+ is accurate and reliable, but we did this ourselves, and it needs independent verification, which the University of Chicago will provide," he added.

Price: C\$0.15

Market Cap: C\$8.96M

1 Year Share Price Graph



Share Information

Code: VPT

Listing: TSX-V

52 week High Low
0.51p 0.135p

Sector: Health Care, Equipment & Services

Website: www.ventripoint.com

Company Synopsis:

Ventripoint (TSXV: VPT) has redesigned VMS to meet the demands of every market. Preparing to move beyond the Left and Right Ventricle to become the first platform to offer 3D volumes for all cardiac chambers, with accuracy equivalent to MRI. all from the convenience of 2D Ultrasound.

Author:

Giles Gwinnett

+44(0)1202770386

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com



No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.